Kombiglyze XR Side Effects
Diarrhea, nausea and vomiting, and common cold symptoms are among the commonly expected side effects of Kombiglyze XR. Fortunately, if such problems do occur, they are usually mild and easily treated. However, potentially serious reactions are also possible, such as allergic reactions and lactic acidosis. These side effects should be reported to a healthcare provider right away.
An Introduction to Kombiglyze XR Side EffectsAs with any medicine, side effects are possible with Kombiglyze™ XR (saxagliptin/metformin ER). However, not everyone who takes the medication will have problems. In fact, most people tolerate it quite well. If side effects do occur, in most cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider.
(This article covers many, but not all, of the possible side effects with Kombiglyze XR. Your healthcare provider can discuss a more complete list with you.)
Common Side Effects of Kombiglyze XR
The two individual active ingredients in Kombiglyze XR -- saxagliptin and extended-release metformin (metformin ER) -- have each been studied extensively. The specific combination in Kombiglyze XR (saxagliptin plus an extended-release metformin product) has not been studied.
However, Kombiglyze XR was approved as a type 2 diabetes treatment based on the studies that combined saxagliptin plus short-acting, immediate-release metformin.
Based on these studies, possible common Kombiglyze XR side effects might include:
- Diarrhea -- in up to 9.9 percent of people
- Upper respiratory tract infection (such as the common cold) -- up to 7.7 percent
- Headaches -- up to 7.5 percent
- Common cold symptoms (such as a runny nose or sore throat) -- up to 6.9 percent
- Urinary tract infection (UTI), such as a bladder infection -- up to 6.8 percent
- Nausea and/or vomiting -- up to 6.5 percent
- Sinus infection and irritation -- up to 2.9 percent
- Abdominal pain (stomach pain) -- up to 2.4 percent
- Irritation and inflammation of the stomach and intestines (gastroenteritis) -- up to 2.3 percent.